Clinical Trial Update: High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating high-dose cytarabine followed by pembrolizumab in relapsed/refractory acute myeloid leukemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Acute Myeloid Leukemia, in Relapse | Phase 2 | Status: COMPLETED | Results posted: 2021-09-05